1. Trang chủ
  2. » Y Tế - Sức Khỏe

Optimal Heart Failure Management potx

102 172 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 102
Dung lượng 5,58 MB

Nội dung

Optimal Heart Failure Management Daniel D Borgeson, MD, FACC, FASE Assistant Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic, Rochester, MN Borgeson.daniel@mayo.edu Mayo Clinic Rochester MN November 4th, 2011 Disclosures: None Heart Failure Management LV Systolic Dysfunction Heart failure With normal Left Ventricular Ejection Fraction Tricuspid Regurgitation COPD Sleep Apnea Right Heart Faiure Mitral Regurgitation Cardio-Renal Syndrome Coronary Artery Disease Diabetes Degenerative Joint Disease Dementia Atrial Fibrillation [...]... What about Heart failure with Normal Ejection Fraction Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF 40 HR 0.92 95% CI 0.70-1.21 P=0.545 30 Placebo Heart failure Hospitalization or death 20 (%) Perindopril 10 0 0 1 Pt at risk (no.) 424 374 426 356 Cleland et al European Heart Journal 27:2238 2 3 184 186 70 69 Years CP1265575-2 Perindopril In Elderly with Chronic Heart Failure (PEP-CHF)... at the right dose, for the right reason Heart Failure Management Details Medications that Demonstrated Survival Benefit ACE Inhibitors • Genally thought to be a class effect, first line therapy • Improves survival • Improves LV ejection fraction • Improves symptoms • Renal protective in diabetics • Decrease MI in patients with CAD SOLVD Trial: Congestive Heart Failure 0.3 Event rate Risk reduction=37%... digoxin; follow-up 6 months; placebo (n=84), carvedilol (n=261) *Multicenter Oral Carvedilol Heart Failure Assessment †Mortality was not a planned endpoint in this study Adapted from Bristow et al Circulation 1996;94:2807-2816 ‡P.05 §P=.07 vs placebo vs placebo Use of Carvedilol Added to ACE Inhibitors in Heart Failure • Optimize volume status • Start at the lowest possible dose • 3.125 mg bid • Increase... hazard ratio 0.85, P=0.010 10 0 0.0 0.5 1.0 No at risk Candesartan Placebo Lancet 362, 2003 1,276 1,272 1,176 1,136 1.5 2.0 Years 1,063 1,013 2.5 3.0 3.5 948 906 457 422 CP1154535-25 How about ARB’s in Heart Failure with Normal Left Ventricular Ejection Fraction CHARM Preserved: Cardiovascular Death or ReHospitalization Proportion with CV death or hospital admission for CHF (%) 50 Hazard ratio 0.89 (95%...Individualization of Therapy • Importance of Co-morbidities • Atrial fibrillation (tachycardia) • Hypertension • Ongoing Ischemia • Diabetes • DJD (NSAID use) • Renal failure • Sleep apnea Survival Benefit Pharmacological Therapy YES ACE Inhibitor YES YES Beta Blocker YES YES Aldosterone Inhibitor YES ???? Diuretic YES No Digoxin LBBB CRT . Disclosures: None Heart Failure Management LV Systolic Dysfunction Heart failure With normal Left Ventricular Ejection Fraction Tricuspid Regurgitation COPD Sleep Apnea Right Heart Faiure. Optimal Heart Failure Management Daniel D Borgeson, MD, FACC, FASE Assistant Professor of Medicine Mayo. this be an Atypical Presentation of Coronary artery Disease? Medical Management of Heart Failure Principles of Medical Management • Only Three Types of Medications • Medications that improve

Ngày đăng: 20/06/2014, 12:20

TỪ KHÓA LIÊN QUAN